Overview

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Hydrochlorothiazide